Leo Pharma looks towards billion-dollar market after phase III success

If everything goes to plan, Leo Pharma will become the second company in the world to lauch a biological drug against eczema. Research director Kim Kjøller has big expectations for the drug, which will compete with Sanofi's blockbuster drug Dupixent.

Photo: Marcus Trappaud Bjørn/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles